{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:50:35Z","timestamp":1787226635826,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2017YFC0908404"],"award-info":[{"award-number":["2017YFC0908404"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This phase 1 trial evaluated the safety, preliminary efficacy, and pharmacokinetics of surufatinib, a small molecular tyrosine kinase inhibitor, combined with toripalimab, a programmed cell death protein-1 antibody, in patients with advanced solid tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is an open-label, dose-escalation and expansion study in patients with solid tumors who had failed standard therapies or had no effective treatment. In the dose-escalation stage, patients were treated with surufatinib, at dose levels of 200, 250, or 300\u00a0mg once daily (QD) in combination with toripalimab 240\u00a0mg, every 3\u00a0weeks (Q3W), to estimate maximum tolerated dose. Additional patients were enrolled in the dose expansion stage to further assess the efficacy, safety, and pharmacokinetics profile. Recommended phase 2 dose (RP2D) was determined based on the safety, tolerability, and preliminary efficacy from dose-escalation and expansion stages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From Feb 14, 2019 to Dec 20, 2020, 33 patients were screened, of which 30 patients were enrolled. One patient in the 300\u00a0mg cohort experienced dose limited toxicity, a grade 3 hyperthyroidism. The most frequent treatment-related adverse events of grade\u2009\u2265\u20093 were hypertension (20.0%), transaminases increased (13.3%), and blood bilirubin increased (13.3%). No treatment-related death or treatment discontinuation was identified. The RP2D was determined to be surufatinib 250\u00a0mg QD plus toripalimab 240\u00a0mg Q3W. Objective response rate was 24.1% (95% confidence interval 10.3\u201243.5%) in this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Surufatinib plus toripalimab was well tolerated, with no unexpected safety signals, and showed preliminary anti-tumor activity in patients with advanced solid tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov Identifier: NCT03879057; registration date: March 18, 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03898-8","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T12:24:29Z","timestamp":1644927869000},"page":"779-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial"],"prefix":"10.1007","volume":"149","clinical-trial-number":[{"clinical-trial-number":"nct03879057","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yanshuo","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"issue":"4","key":"3898_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida W, Cheng ML, Armenia J et al (2019) Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 5(4):471\u2013478. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5801","journal-title":"JAMA Oncol"},{"issue":"3","key":"3898_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Plimack ER, Puzanov I et al (2018) Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 19(3):405\u2013415. https:\/\/doi.org\/10.1016\/S1470-2045(18)30081-0","journal-title":"Lancet Oncol"},{"issue":"1","key":"3898_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm1699","volume":"14","author":"RJ Buckanovich","year":"2008","unstructured":"Buckanovich RJ, Facciabene A, Kim S et al (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14(1):28\u201336. https:\/\/doi.org\/10.1038\/nm1699","journal-title":"Nat Med"},{"key":"3898_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2020","unstructured":"Carmeliet P, Jain RK (2020) Angiogenesis in cancer and other diseases. Nature 407:249\u2013257. https:\/\/doi.org\/10.1038\/35025220","journal-title":"Nature"},{"issue":"9","key":"3898_CR5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1089\/thy.2019.0453","volume":"30","author":"J Chen","year":"2020","unstructured":"Chen J, Ji Q, Bai C et al (2020) Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial. Thyroid 30(9):1245\u20131253. https:\/\/doi.org\/10.1089\/thy.2019.0453","journal-title":"Thyroid"},{"issue":"26","key":"3898_CR6","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX et al (2020) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38(26):2960\u20132970. https:\/\/doi.org\/10.1200\/JCO.20.00808","journal-title":"J Clin Oncol"},{"issue":"18","key":"3898_CR7","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N et al (2020) Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 38(18):2053\u20132061. https:\/\/doi.org\/10.1200\/JCO.19.03296","journal-title":"J Clin Oncol"},{"issue":"1","key":"3898_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11864-013-0268-y","volume":"15","author":"A Gunturi","year":"2014","unstructured":"Gunturi A, McDermott DF (2014) Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol 15(1):137\u2013146. https:\/\/doi.org\/10.1007\/s11864-013-0268-y","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"3898_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","volume":"20","author":"RS Herbst","year":"2019","unstructured":"Herbst RS, Arkenau HT, Santana-Davila R et al (2019) Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial. Lancet Oncol 20(8):1109\u20131123. https:\/\/doi.org\/10.1016\/S1470-2045(19)30458-9","journal-title":"Lancet Oncol"},{"issue":"5","key":"3898_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ (2019) Toripalimab: first global approval. Drugs 79(5):573\u2013578. https:\/\/doi.org\/10.1007\/s40265-019-01076-2","journal-title":"Drugs"},{"issue":"26","key":"3898_CR11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"issue":"10","key":"3898_CR12","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","volume":"26","author":"M Lu","year":"2020","unstructured":"Lu M, Zhang P, Zhang Y et al (2020) Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial. Clin Cancer Res 26(10):2337\u20132345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-4000","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3898_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker V, Rasco D, Vogelzang NJ et al (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20(5):711\u2013718. https:\/\/doi.org\/10.1016\/S1470-2045(19)30020-8","journal-title":"Lancet Oncol"},{"issue":"2","key":"3898_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2016.10.003","volume":"12","author":"C Manegold","year":"2017","unstructured":"Manegold C, Dingemans AC, Gray JE et al (2017) The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol 12(2):194\u2013207. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.003","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"3898_CR15","doi-asserted-by":"publisher","first-page":"e16162","DOI":"10.1200\/JCO.2018.36.15_suppl.e16162","volume":"36","author":"PW McGarrah","year":"2018","unstructured":"McGarrah PW, Leventakos K, Hobday TJ et al (2018) Efficacy of 2nd-line chemotherapy in patients with poorly differentiated, high grade extrapulmonary neuroendocrine carcinoma (PD NEC). J Clin Oncol 36(15_suppl):e16162","journal-title":"J Clin Oncol"},{"key":"3898_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107281","volume":"91","author":"DC Mo","year":"2021","unstructured":"Mo DC, Luo PH, Huang SX, Wang HL, Huang JF (2021) Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review. Int Immunopharmacol 91:107281. https:\/\/doi.org\/10.1016\/j.intimp.2020.107281","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"3898_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"issue":"10","key":"3898_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14712598.2018.1522300","volume":"18","author":"K Ninomiya","year":"2018","unstructured":"Ninomiya K, Hotta K (2018) Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opin Biol Ther 18(10):1015\u20131021. https:\/\/doi.org\/10.1080\/14712598.2018.1522300","journal-title":"Expert Opin Biol Ther"},{"key":"3898_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fonc.2019.00396","volume":"9","author":"AF Oliveira","year":"2019","unstructured":"Oliveira AF, Bretes L, Furtado I (2019) Review of PD-1\/PD-L1 inhibitors in metastatic dMMR\/MSI-H colorectal cancer. Front Oncol 9:396. https:\/\/doi.org\/10.3389\/fonc.2019.00396","journal-title":"Front Oncol"},{"issue":"12","key":"3898_CR20","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack E, Souli\u00e8res D et al (2020) (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21(12):1563\u20131573","journal-title":"Lancet Oncol"},{"issue":"10189","key":"3898_CR21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, Powles T, Atkins MB et al (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393(10189):2404\u20132415. https:\/\/doi.org\/10.1016\/S0140-6736(19)30723-8","journal-title":"Lancet"},{"issue":"4","key":"3898_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"3898_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:205\u2013214. https:\/\/doi.org\/10.1016\/j.cell.2015.03.030","journal-title":"Cell"},{"issue":"32","key":"3898_CR24","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","volume":"37","author":"X Sheng","year":"2019","unstructured":"Sheng X, Yan X, Chi Z et al (2019) Axitinib in combination with toripalimab, a humanized immunoglobulin g4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase Ib trial. J Clin Oncol 37(32):2987\u20132999. https:\/\/doi.org\/10.1200\/JCO.19.00210","journal-title":"J Clin Oncol"},{"issue":"24","key":"3898_CR25","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"issue":"5667","key":"3898_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/274168a0","volume":"274","author":"ER Stanley","year":"1978","unstructured":"Stanley ER, Chen DM, Lin HS (1978) Induction of macrophage production and proliferation by a purified colony stimulating factor. Nature 274(5667):168\u2013170. https:\/\/doi.org\/10.1038\/274168a0","journal-title":"Nature"},{"key":"3898_CR27","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"issue":"9","key":"3898_CR28","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13(9):1302\u20131311. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.013","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3898_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","volume":"30","author":"F Wang","year":"2019","unstructured":"Wang F, Wei XL, Wang FH et al (2019) Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432. Ann Oncol 30(9):1479\u20131486. https:\/\/doi.org\/10.1093\/annonc\/mdz197","journal-title":"Ann Oncol"},{"issue":"12","key":"3898_CR30","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-18-2994","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J, Li J, Bai C et al (2019) Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib\/II trial. Clin Cancer Res 25(12):3486\u20133494. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2994","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3898_CR31","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Shen L, Zhou Z et al (2020a) Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(11):1500\u20131512. https:\/\/doi.org\/10.1016\/S1470-2045(20)30496-4","journal-title":"Lancet Oncol"},{"issue":"11","key":"3898_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Shen L, Bai C et al (2020b) Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(11):1489\u20131499. https:\/\/doi.org\/10.1016\/S1470-2045(20)30493-9","journal-title":"Lancet Oncol"},{"key":"3898_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.01.028","volume":"130","author":"J Yang","year":"2020","unstructured":"Yang J, Dong L, Yang S et al (2020) Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. Eur J Cancer 130:182\u2013192. https:\/\/doi.org\/10.1016\/j.ejca.2020.01.028","journal-title":"Eur J Cancer"},{"key":"3898_CR34","doi-asserted-by":"publisher","unstructured":"Zhou J, Ni J, Cheng M et al (2017) Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR-1 and CSF-1R kinases. AACR Abstract 77(13). https:\/\/doi.org\/10.1158\/1538-7445.AM2017-4187","DOI":"10.1158\/1538-7445.AM2017-4187"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03898-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T07:08:43Z","timestamp":1676617723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03898-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3898"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03898-8","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"6 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This clinical trial was approved by Ethics Committee of Peking University Cancer Hospital and was conducted strictly in accordance with the Declaration of Helsinki and Good Clinical Practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent form (ICF) before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}